GlassScriptPhysician profile
Smitha R Voleti
NPI 1811216856
$5,349.00
in general payments reported to CMS, 2019-2025
26 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $224 · 2021: $493 · 2022: $400 · 2023: $523 · 2024: $1,627 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $837.70 | 2022-2025 | |
| Alcon Vision LLC | $776.32 | 2019-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Aerie Pharmaceuticals, INC. | $607.77 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $383.12 | 2019-2021 | |
| Rxsight INC | $319.35 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Glaukos Corporation | $317.63 | 2024-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Sun Pharmaceutical Industries INC. | $287.92 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $279.80 | 2019 | |
| Sight Sciences, INC. | $249.50 | 2022-2024 | Omni Surgical System |
| Allergan, INC. | $208.68 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $196.93 | 2022-2024 | Tecnis Iol, Tecnis Iol |
| Bausch & Lomb Americas INC. | $165.45 | 2023-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| New World Medical,INC. | $150.19 | 2022 | |
| Harrow Eye, LLC | $116.09 | 2024-2025 | Vevye |
| Amgen INC. | $95.21 | 2024-2025 | Tepezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $57.30 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.07 | 2019 | |
| Oyster Point Pharma, INC. | $49.96 | 2024 | Tyrvaya |
| Thea Pharma INC. | $47.59 | 2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $30.36 | 2025 | Xdemvy |
| Eyepoint US, INC. | $28.33 | 2019 | |
| Rayner Intraocular Lenses Limited | $26.23 | 2025 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Ani Pharmaceuticals, INC. | $20.98 | 2025 | Iluvien |
| Genentech USA, INC. | $18.92 | 2025 | Vabysmo |
| Spark Therapeutics, INC. | $11.68 | 2019 | |
| Genzyme Corporation | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Voleti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.